Perioperative antibiotherapy should replace prophylactic antibiotics in patients undergoing pancreaticoduodenectomy preceded by preoperative biliary drainage.


Journal

Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 31 05 2019
accepted: 23 06 2019
pubmed: 13 7 2019
medline: 7 9 2019
entrez: 13 7 2019
Statut: ppublish

Résumé

Pancreaticoduodenectomy (PD) remains a morbid surgery. Preoperative biliary drainage (PBD) is often necessary before surgery but is associated with biliary contamination. We compared the postoperative complications of patients undergoing PBD who received the usual prophylactic antibiotics (PAs) or systematic antibiotherapy (ABT). All patients who underwent surgery between 2008 and 2017 were included. Systematic perioperative ABT with piperacillin + tazobactam (ABT group) was implemented in 2014 as the standard of care for PBD. Patients treated in the period before such implementation, during which standard cefazolin was given, served as the controls (PAs group). The primary outcomes were postoperative complications. We included 122 patients with PBD who underwent surgery. There were no demographic differences between the two groups. Perioperative ABT was associated with a reduction in deep abdominal abscesses (36% vs 10%, P = .0008), respiratory tract infections (15% vs 3%; P = .02), bacteremia (41% vs 6%; P < .0001), and a shorter length of hospital stay (17 [13-27] vs 13 [10-14] days; P < .0001). ABT was a protective factor against the development of deep abdominal abscesses (odds ratio [OR] = 0.16; P = .001) whereas smoking (OR = 3.9) and pancreatic fistula (OR = 19.1) were risk factors. Systematic perioperative ABT in patients undergoing PD preceded by PBD may reduce deep surgical infections and the length of hospital stay.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
Pancreaticoduodenectomy (PD) remains a morbid surgery. Preoperative biliary drainage (PBD) is often necessary before surgery but is associated with biliary contamination. We compared the postoperative complications of patients undergoing PBD who received the usual prophylactic antibiotics (PAs) or systematic antibiotherapy (ABT).
METHODS METHODS
All patients who underwent surgery between 2008 and 2017 were included. Systematic perioperative ABT with piperacillin + tazobactam (ABT group) was implemented in 2014 as the standard of care for PBD. Patients treated in the period before such implementation, during which standard cefazolin was given, served as the controls (PAs group). The primary outcomes were postoperative complications.
RESULTS RESULTS
We included 122 patients with PBD who underwent surgery. There were no demographic differences between the two groups. Perioperative ABT was associated with a reduction in deep abdominal abscesses (36% vs 10%, P = .0008), respiratory tract infections (15% vs 3%; P = .02), bacteremia (41% vs 6%; P < .0001), and a shorter length of hospital stay (17 [13-27] vs 13 [10-14] days; P < .0001). ABT was a protective factor against the development of deep abdominal abscesses (odds ratio [OR] = 0.16; P = .001) whereas smoking (OR = 3.9) and pancreatic fistula (OR = 19.1) were risk factors.
CONCLUSION CONCLUSIONS
Systematic perioperative ABT in patients undergoing PD preceded by PBD may reduce deep surgical infections and the length of hospital stay.

Identifiants

pubmed: 31297827
doi: 10.1002/jso.25622
doi:

Substances chimiques

Anti-Bacterial Agents 0
Piperacillin, Tazobactam Drug Combination 157044-21-8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

639-645

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

O Degrandi (O)

Department of Digestive And Endocrinology Surgery, Centre for Digestive System Diseases, Magellan, University Hospital of Bordeaux, Pessac, France.
Department of tissus engineering, INSERM UMR 1026, University of Bordeaux, Bordeaux, France.
Department of Research, INSERM UMR 1035, University of Bordeaux, Bordeaux, France.

E Buscail (E)

Department of Digestive And Endocrinology Surgery, Centre for Digestive System Diseases, Magellan, University Hospital of Bordeaux, Pessac, France.
Department of Research, INSERM UMR 1035, University of Bordeaux, Bordeaux, France.

S Martellotto (S)

Department of Digestive And Endocrinology Surgery, Centre for Digestive System Diseases, Magellan, University Hospital of Bordeaux, Pessac, France.

C Gronnier (C)

Department of Digestive And Endocrinology Surgery, Centre for Digestive System Diseases, Magellan, University Hospital of Bordeaux, Pessac, France.
Department of tissus engineering, INSERM UMR 1026, University of Bordeaux, Bordeaux, France.

D Collet (D)

Department of Digestive And Endocrinology Surgery, Centre for Digestive System Diseases, Magellan, University Hospital of Bordeaux, Pessac, France.
Department of tissus engineering, INSERM UMR 1026, University of Bordeaux, Bordeaux, France.

J P Adam (JP)

Department of Digestive And Endocrinology Surgery, Centre for Digestive System Diseases, Magellan, University Hospital of Bordeaux, Pessac, France.

A Ouattara (A)

Department of Biology of Cardiovascular Diseases, INSERM UMR 1034, University of Bordeaux, Pessac, France.
Department of Anaesthesia and Critical Care, Magellan Medico-Surgical Center, CHU Bordeaux, Bordeaux, France.

C Laurent (C)

Department of Digestive And Endocrinology Surgery, Centre for Digestive System Diseases, Magellan, University Hospital of Bordeaux, Pessac, France.
Department of Research, INSERM UMR 1035, University of Bordeaux, Bordeaux, France.

A Dewitte (A)

Department of Biology of Cardiovascular Diseases, INSERM UMR 1034, University of Bordeaux, Pessac, France.
Department of Anaesthesia and Critical Care, Magellan Medico-Surgical Center, CHU Bordeaux, Bordeaux, France.

L Chiche (L)

Department of Digestive And Endocrinology Surgery, Centre for Digestive System Diseases, Magellan, University Hospital of Bordeaux, Pessac, France.
Department of Research, INSERM UMR 1035, University of Bordeaux, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH